Edith Mitchell

TitleProfessor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address233 S. 10th Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    S03RR003086     (MCCALLUM, ROBERT N)Mar 1, 1981 - Feb 29, 1992
    NIH/NCRR
    MINORITY HIGH SCHOOL STUDENT RESEARCH APPRENTICE PROGRAM
    Role: Co-Principal Investigator

    U01CA086127     (MITCHELL, EDITH P.)Apr 4, 2000 - Mar 31, 2006
    NIH/NCI
    SPECIAL POPULATIONS NETWORK FOR CANCER CONTROL
    Role: Principal Investigator

    R01CA148565     (WICKSTROM, ERIC)Jul 1, 2010 - Apr 30, 2014
    NIH/NCI
    PET Imaging of KRAS2 Activation to Guide EGFR Targeting in Cancer Therapy
    Role: Co-Principal Investigator

    UG1CA233341     (MITCHELL, EDITH P.)Mar 5, 2019 - Feb 29, 2024
    NIH/NCI
    Sidney Kimmel Cancer Center LAPS Institutional Collaboration
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mitchell EP. Declines in Cancer Screening During COVID-19 Pandemic. J Natl Med Assoc. 2020 Dec; 112(6):563-564. PMID: 33339569.
      Citations:    
    2. Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Zwiebel JA, Rubinstein LV, Little RF, Arteaga CL, Comis R, Abrams JS, O'Dwyer PJ, Conley BA. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 Nov 20; 38(33):3883-3894. PMID: 33048619.
      Citations:    
    3. Au C, Gupta E, Khaing P, Dibello J, Chengsupanimit T, Mitchell EP, West FM, Baram M, Awsare BK, Kane GC. Clinical presentations and outcomes in pulmonary embolism patients with cancer. J Thromb Thrombolysis. 2020 Oct 12. PMID: 33047244.
      Citations:    
    4. Mitchell EP. Risk Trends in Colorectal Cancer. J Natl Med Assoc. 2020 Oct; 112(5):445. PMID: 33292929.
      Citations:    
    5. Mitchell EP. National Medical Association Celebrates the 125th Anniversary: Much Done, But Lots More to Do. J Natl Med Assoc. 2020 Oct; 112(5S):S1. PMID: 33308710.
      Citations:    
    6. Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol. 2020 Aug 06; JCO2000762. PMID: 32758030.
      Citations:    
    7. Mitchell EP. The National Medical Association 1895-2020: Struggle for Healthcare Equity in the United States of America. J Natl Med Assoc. 2020 Aug; 112(4):331-332. PMID: 32891361.
      Citations:    
    8. Savitch SL, Grenda TR, Scott W, Cowan SW, Posey J, Mitchell EP, Cohen SJ, Yeo CJ, Evans NR. Racial Disparities in Rates of Surgery for Esophageal Cancer: a Study from the National Cancer Database. J Gastrointest Surg. 2020 Jun 04. PMID: 32500418.
      Citations:    
    9. Mitchell EP. COVID-19 Innovations: Addressing Rapidly Changing Clinical Needs. J Natl Med Assoc. 2020 Jun; 112(3):237-238. PMID: 32709271.
      Citations:    
    10. Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020 May 28; JCO1902630. PMID: 32463741.
      Citations:    
    11. Odnokoz O, Yu P, Peck AR, Sun Y, Kovatich AJ, Hooke JA, Hu H, Mitchell EP, Rui H, Fuchs SY. Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. Cancer Biol Ther. 2020 May 07; 1-8. PMID: 32378445.
      Citations:    
    12. Mitchell EP. Corona Virus: Global Pandemic Causing World-Wide Shutdown. J Natl Med Assoc. 2020 Apr 03. PMID: 32253007.
      Citations:    
    13. Mitchell EP. 2020 Vision: Continuing Declines in Cancer Incidence and Mortality Rates. J Natl Med Assoc. 2020 Feb; 112(1):1-2. PMID: 32169164.
      Citations:    
    14. Johnson DB, Zhao F, Noel MS, Riely GJ, Mitchell EP, Wright JJ, Chen HX, Gray RJ, Li S, McShane LM, Rubinstein L, Patton D, Williams M, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131). Clin Cancer Res. 2020 Jan 10. PMID: 31924734.
      Citations:    
    15. Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, Wagner LI, Sloan J, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, Santala R, Cripps C, Weis JR, Atkins JN, Leichman CG, Petrelli NJ, Sinicrope FA, Brierley JD, Tepper JE, O'Dwyer PJ, Sigurdson ER, Hamilton SR, Cella D, Benson AB. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). Oncologist. 2019 Dec 18. PMID: 31852811.
      Citations:    
    16. Mitchell EP. Attacking Cancer Death Rates. J Natl Med Assoc. 2019 Dec; 111(6):577. PMID: 31862094.
      Citations:    
    17. Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, Sharon E, Streicher H, Li S, McShane LM, Rubinstein L, Patton DR, Williams PM, Coffey B, Hamilton SR, Bahary N, Suga JM, Hatoum H, Abrams JS, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Chen AP, Flaherty KT. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol. 2020 Jan 20; 38(3):214-222. PMID: 31765263.
      Citations:    
    18. Mitchell EP. The National Medical Association: Moving Forward to Eliminate Healthcare Disparities but Keeping Watch Through the Rear View Mirror. J Natl Med Assoc. 2019 Oct; 111(5):467-468. PMID: 31856955.
      Citations:    
    19. Sadigh G, Gallagher K, Obenchain J, Benson A, Mitchell E, Sengupta S, Carlos RC. Pilot Feasibility Study of an Oncology Financial Navigation Program in Brain Cancer Patients. J Am Coll Radiol. 2019 Oct; 16(10):1420-1424. PMID: 31585660.
      Citations:    
    20. Plasterer C, Tsaih SW, Peck AR, Chervoneva I, O'Meara C, Sun Y, Lemke A, Murphy D, Smith J, Ran S, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Bergom C, Joshi A, Auer P, Prokop J, Rui H, Flister MJ. Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome. Breast Cancer Res Treat. 2019 Aug; 177(1):77-91. PMID: 31165373.
      Citations:    
    21. Parikh AR, Lee FC, Yau L, Koh H, Knost J, Mitchell EP, Bosanac I, Choong N, Scappaticci FA, Mancao C, Lenz HJ. MAVERICC, a randomized, biomarker-stratified, phase 2 study of mFOLFOX6-bevacizumab vs FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clin Cancer Res. 2018 Sep 17. PMID: 30224341.
      Citations:    
    22. Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo JP, Bibbo M, Auer PW, Flister MJ, Hyslop T, Mitchell EP, Chervoneva I, Rui H. Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling. Clin Cancer Res. 2018 Aug 10. PMID: 30097435.
      Citations:    
    23. Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clin Colorectal Cancer. 2017 Dec 13. PMID: 29576427.
      Citations:    
    24. Frazer E, Mitchell RA, Nesbitt LS, Williams M, Mitchell EP, Williams RA, Browne D. The Violence Epidemic in the African American Community: A Call by the National Medical Association for Comprehensive Reform. J Natl Med Assoc. 2018 Feb; 110(1):4-15. PMID: 29510842.
      Citations:    
    25. Winkfield KM, Flowers CR, Patel JD, Rodriguez G, Robinson P, Agarwal A, Pierce L, Brawley OW, Mitchell EP, Head-Smith KT, Wollins DS, Hayes DF. American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce. J Clin Oncol. 2017 Aug 01; 35(22):2576-2579. PMID: 28459634.
      Citations:    
    26. Garg MK, Zhao F, Sparano JA, Palefsky J, Whittington R, Mitchell EP, Mulcahy MF, Armstrong KI, Nabbout NH, Kalnicki S, El-Rayes BF, Onitilo AA, Moriarty DJ, Fitzgerald TJ, Benson AB. Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol. 2017 Mar; 35(7):718-726. PMID: 28068178.
      Citations:    
    27. Bernard B, Muralidhar V, Chen YH, Sridhar SS, Mitchell EP, Pettaway CA, Carducci MA, Nguyen PL, Sweeney CJ. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017 May 01; 123(9):1536-1544. PMID: 28055108.
      Citations:    
    28. Winkfield KM, Flowers CR, Mitchell EP. Making the Case for Improving Oncology Workforce Diversity. Am Soc Clin Oncol Educ Book. 2017; 37:18-22. PMID: 28561643.
      Citations:    
    29. Davey MP, Bilkins B, Diamond G, Willis AI, Mitchell EP, Davey A, Young FM. African American Patients' Psychosocial Support Needs and Barriers to Treatment: Patient Needs Assessment. J Cancer Educ. 2016 Sep; 31(3):481-7. PMID: 26048632.
      Citations:    
    30. Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 2016 Aug; 39(4):340-5. PMID: 24685886.
      Citations:    
    31. Peck AR, Girondo MA, Liu C, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Freydin B, Hyslop T, Chervoneva I, Rui H. Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms. Mod Pathol. 2016 Oct; 29(10):1143-54. PMID: 27312066.
      Citations:    
    32. Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016 Jun; 11(3):383-400. PMID: 26706237.
      Citations:    
    33. Mitchell EP. The National Medical Association: True North Toward Health Care Equity. J Natl Med Assoc. 2016 Feb; 108(1):1-3. PMID: 26928482.
      Citations:    
    34. Chen Y, Bekhash A, Kovatich AJ, Hooke JA, Liu J, Kvecher L, Fantacone-Campbell JL, Mitchell EP, Rui H, Mural RJ, Shriver CD, Hu H. Positive Association of Fibroadenomatoid Change with HER2-Negative Invasive Breast Cancer: A Co-Occurrence Study. PLoS One. 2015; 10(6):e0129500. PMID: 26098961.
      Citations:    
    35. Hecht JR, Mitchell EP, Yoshino T, Welslau M, Lin X, Chow Maneval E, Paolini J, Lechuga MJ, Kretzschmar A. 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study. Cancer Manag Res. 2015; 7:165-73. PMID: 26109878.
      Citations:    
    36. Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2015 Jan 1; 91(1):116-23. PMID: 25446610.
      Citations:    
    37. Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, Davidenko I, Stephenson J, Elez E, Prenen H, Deng H, Tang R, McCaffery I, Oliner KS, Chen L, Gansert J, Loh E, Smethurst D, Tabernero J. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res. 2014 Aug 15; 20(16):4240-50. PMID: 24919569.
      Citations:    
    38. Zhao F, Chang VT, Cleeland C, Cleary JF, Mitchell EP, Wagner LI, Fisch MJ. Determinants of Pain Severity Changes in Ambulatory Patients With Cancer: An Analysis From Eastern Cooperative Oncology Group Trial E2Z02. J Clin Oncol. 2014 Feb 1; 32(4):312-9. PMID: 24366929.
      Citations:    
    39. Paudyal B, Zhang K, Chen CP, Wampole ME, Mehta N, Mitchell EP, Gray BD, Mattis JA, Pak KY, Thakur ML, Wickstrom E. Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA. Nucl Med Biol. 2013 Nov; 40(8):994-9. PMID: 24074944.
      Citations:    
    40. Wampole ME, Kairys JC, Mitchell EP, Ankeny ML, Thakur ML, Wickstrom E. Consistent Surgeon Evaluations of Three-Dimensional Rendering of PET/CT Scans of the Abdomen of a Patient with a Ductal Pancreatic Mass. PLoS One. 2013; 8(9):e75237. PMID: 24086475.
      Citations:    
    41. Mohiuddin M, Paulus R, Mitchell E, Hanna N, Yuen A, Nichols R, Yalavarthi S, Hayostek C, Willett C. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 1; 86(3):523-8. PMID: 23545284.
      Citations:    
    42. Mitchell EP. Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clin Colorectal Cancer. 2013 Jun; 12(2):73-85. PMID: 23102896.
      Citations:    
    43. Yoder MC, Bannon JP, Mitchell EP, Morris GJ. Mucinous colloid carcinoma of the colon metastatic to the breast. Semin Oncol. 2012 Jun; 39(3):e1-7. PMID: 22595059.
      Citations:    
    44. Hurwitz H, Mitchell EP, Cartwright T, Kwok A, Hu S, McKenna E, Patt YZ. A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). Oncologist. 2012; 17(7):937-46. PMID: 22622147.
      Citations:    
    45. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012; 7(1):e29794. PMID: 22272248.
      Citations:    
    46. Mitchell EP, Piperdi B, Lacouture ME, Shearer H, Iannotti N, Pillai MV, Xu F, Yassine M. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin Colorectal Cancer. 2011 Dec; 10(4):333-9. PMID: 22000810.
      Citations:    
    47. Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):1367-75. PMID: 21775070.
      Citations:    
    48. Showalter TN, Zhan T, Anne PR, Chervoneva I, Mitchell EP, Yeo CJ, Rosato EL, Kennedy EP, Berger AC. The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma. J Gastrointest Surg. 2011 Aug; 15(8):1411-6. PMID: 21523621.
      Citations:    
    49. Fogh SE, Yu A, Kubicek GJ, Scott W, Mitchell E, Rosato EL, Berger AC. Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy? Int J Radiat Oncol Biol Phys. 2011 Aug 1; 80(5):1372-6. PMID: 21106309.
      Citations:    
    50. Gonsalves CF, Mitchell EP, Brown DB. Management of hypersplenism by partial splenic embolization with ethylene vinyl alcohol copolymer. AJR Am J Roentgenol. 2010 Nov; 195(5):1241-4. PMID: 20966334.
      Citations:    
    51. Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, Sotgia F, Brody JR, Mitchell EP, Lisanti MP. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther. 2010 Jul; 10(2):135-43. PMID: 20431349.
      Citations:    
    52. Noto KA, Almario C, Maxwell PJ, Mitchell EP, Isenberg GA, Goldstein SD. Long-term survival after colonic stenting and restenting for malignant colonic obstruction. Am Surg. 2010 Apr; 76(4):457-9. PMID: 20420267.
      Citations:    
    53. Hecht JR, Mitchell E, Neubauer MA, Burris HA, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J, Berlin J. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res. 2010 Apr 1; 16(7):2205-13. PMID: 20332321.
      Citations:    
    54. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010 Mar 10; 28(8):1351-7. PMID: 20142600.
      Citations:    
    55. Showalter SL, Rosato EL, Anne PR, Scott W, Mitchell E, Berger AC. Does diabetes mellitus influence pathologic complete response and tumor downstaging after neoadjuvant chemoradiation for esophageal and gastroesophageal cancer? A two-institution report. J Surg Oncol. 2010 Jan 1; 101(1):43-6. PMID: 19798684.
      Citations:    
    56. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Aug 10; 27(23):3778-85. PMID: 19581537.
      Citations:    
    57. Jackson NA, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, Meyerhardt J. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer. 2009 Jun 15; 115(12):2617-29. PMID: 19382200.
      Citations:    
    58. Kim GP, Sargent DJ, Mahoney MR, Rowland KM, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009 Jun 10; 27(17):2848-54. PMID: 19380443.
      Citations:    
    59. Langerak A, River G, Mitchell E, Cheema P, Shing M. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. Clin Colorectal Cancer. 2009 Jan; 8(1):49-54. PMID: 19203897.
      Citations:    
    60. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10; 27(5):672-80. PMID: 19114685.
      Citations:    
    61. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008 Jul 1; 26(19):3213-21. PMID: 18591556.
      Citations:    
    62. Morris GJ, Mitchell EP. Higher incidence of aggressive breast cancers in African-American women: a review. J Natl Med Assoc. 2008 Jun; 100(6):698-702. PMID: 18595572.
      Citations:    
    63. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer. 2008 May; 7(3):184-90. PMID: 18621636.
      Citations:    
    64. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007 Oct 20; 25(30):4779-86. PMID: 17947725.
      Citations:    
    65. Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park). 2007 Oct; 21(11 Suppl 5):4-9. PMID: 18154212.
      Citations:    
    66. Lacouture ME, Cotliar J, Mitchell EP. Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology (Williston Park). 2007 Oct; 21(11 Suppl 5):17-21. PMID: 18154214.
      Citations:    
    67. Intenzo CM, Jabbour S, Lin HC, Miller JL, Kim SM, Capuzzi DM, Mitchell EP. Scintigraphic imaging of body neuroendocrine tumors. Radiographics. 2007 Sep-Oct; 27(5):1355-69. PMID: 17848696.
      Citations:    
    68. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007 Aug 15; 110(4):876-84. PMID: 17620276.
      Citations:    
    69. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007 Apr 20; 25(12):1539-44. PMID: 17442997.
      Citations:    
    70. Morris GJ, Mitchell EP. Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. J Natl Med Assoc. 2007 Jan; 99(1):35-45. PMID: 17304967.
      Citations:    
    71. Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 2006 Nov; 32(7):491-503. PMID: 16959432.
      Citations:    
    72. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006 Sep 1; 24(25):4069-77. PMID: 16943524.
      Citations:    
    73. Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A, Nichols C, Shane R, Hayostek C, Willett C. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 2006 Feb 1; 24(4):650-5. PMID: 16446336.
      Citations:    
    74. Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol. 2006 Feb; 33(1):106-20. PMID: 16473649.
      Citations:    
    75. Mitchell EP. Prognostic impact of race and ethnicity in the treatment of colorectal cancer. Med Clin North Am. 2005 Sep; 89(5):1045-57, 1054. PMID: 16129111.
      Citations:    
    76. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005; 23(4):338-51. PMID: 16100946.
      Citations:    
    77. Halbert CH, Kessler LJ, Mitchell E. Genetic testing for inherited breast cancer risk in African Americans. Cancer Invest. 2005; 23(4):285-95. PMID: 16100940.
      Citations:    
    78. Charara M, Edmonston TB, Burkholder S, Walters R, Anne P, Mitchell E, Fry R, Boman B, Rose D, Fishel R, Curran W, Palazzo J. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res. 2004 Sep-Oct; 24(5B):3161-7. PMID: 15510606.
      Citations:    
    79. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 Jul 15; 22(14):2918-26. PMID: 15254061.
      Citations:    
    80. Ramanathan RK, Clark JW, Kemeny NE, Lenz HJ, Gococo KO, Haller DG, Mitchell EP, Kardinal CG. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol. 2003 Aug 1; 21(15):2904-11. PMID: 12885808.
      Citations:    
    81. Dold FG, Mitchell EP. Sudden-onset thrombocytopenia with oxaliplatin. Ann Intern Med. 2003 Jul 15; 139(2):E156. PMID: 12859182.
      Citations:    
    82. Eiseman AS, Flanagan JC, Brooks AB, Mitchell EP, Pemberton CH. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthal Plast Reconstr Surg. 2003 May; 19(3):216-24. PMID: 12918558.
      Citations:    
    83. Stein DE, Mahmoud NN, Anné PR, Rose DG, Isenberg GA, Goldstein SD, Mitchell E, Fry RD. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum. 2003 Apr; 46(4):448-53. PMID: 12682535.
      Citations:    
    84. Mitchell EP. Prognosis after rectal cancer treatment in blacks and whites: advanced stage at diagnosis or other factors? J Clin Oncol. 2003 Feb 1; 21(3):397-8. PMID: 12560424.
      Citations:    
    Mitchell's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (206)
    Explore
    _
    Co-Authors (35)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _